Search

Displaying results 2831 - 2840 of 5506 in total
  1. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. Bentoquatam contains bentonite, a clay, and is only effective as lon...

  2. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication. … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.

  3. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment. … Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.

  4. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  5. Drug

    Hexetidine

    go.drugbank.com/drugs/DB08958
    ApprovedWithdrawn

    It is used as a 0.1% mouthwash for local infections and oral hygiene.

  6. Drug

    Incadronic acid

    go.drugbank.com/drugs/DB06255
    Experimental

    Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.

  7. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    tumour cells in the CAR T cell preparation. … [A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells

    Categories: Receptors, Antigen, T-Cell, CD19-Directed Genetically Modified Autologous T-cell Immunotherapies
  8. Drug

    Aspergillus niger var. niger

    go.drugbank.com/drugs/DB10426
    Approved

    Aspergillus niger var. niger is a fungus which can provoke allergic reactions. Aspergillus niger var. niger extract is used in allergenic testing.

    Mixtures: Treatment Set TS333938
  9. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    Afamitresgene autoleucel is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a … [L51114] The transduced T cells are expanded, washed, formulated into a suspension, and cryopreserved.

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE
  10. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.